Apellis Pharmaceuticals, Inc. 4

Chief People Officer Kelley Boucher’s 127,804 Apellis common shares and 146,138 in‑the‑money option shares were cancelled and cashed out at $41.00 per share (plus CVRs) in connection with Biogen’s acquisition of Apellis.

On May 14, 2026, in connection with the closing of Biogen Inc.’s acquisition of Apellis Pharmaceuticals, Inc., Chief People Officer Kelley Boucher’s equity holdings were effectively cashed out and cancelled pursuant to the Agreement and Plan of Merger. A total of 127,804 shares of Apellis common stock held directly were disposed of for cash plus contingent value rights (CVRs), and various restricted stock unit (RSU) and performance-based RSU awards were converted into rights to receive cash equal to $41.00 per underlying share (plus one CVR per share) subject to continued service-based vesting. In addition, vested or transaction‑vested stock options with exercise prices of $16.80, $19.39, and $28.17 per share covering 32,976, 67,396, and 45,766 shares, respectively, were cancelled and converted into cash payments equal to the intrinsic value (the excess of $41.00 over the exercise price) plus one CVR per option share. Following these merger-related cash-out transactions, Boucher no longer held any Apellis common stock or stock options, with her equity exposure effectively converted into cash and CVR entitlements rather than ongoing ownership in the now wholly owned subsidiary of Biogen.

Filing Facts

CIK

1492422

Ticker

APLS

Form

4

Source Type

sec

Accession

0001193125-26-224589

Alert Tier

7